Altamira Therapeutics Ltd. (CYTOF) Operating income 2022–2024
Altamira Therapeutics Ltd. (CYTOF) annual operating income history from SEC filings — each fiscal year as reported.
-$6.9MFY2024 · since FY2022: -$18.9M → -$6.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$6.9M | -4.0% |
| FY2023 | -$6.6M | +65.1% |
| FY2022 | -$18.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CYTOF financial trends
CYTOF RevenueCYTOF Net incomeCYTOF Net marginCYTOF Gross profitCYTOF Gross marginCYTOF Operating marginCYTOF Operating cash flowCYTOF Free cash flowCYTOF Capital expendituresCYTOF Return on equityCYTOF Stock buybacksCYTOF Dividends paidCYTOF Total assetsCYTOF Total liabilitiesCYTOF Shareholders’ equityCYTOF overview →